Fitch scores Astrazeneca at ‘A’ hoch | 22.08.24

FRANKFURT (Dow Jones) — Fitch has upgraded Astrazeneca’s long-term issuer cut from ‘A-‘ to ‘A’. The rating is positive, with the rating agent performing best. “The reassessment reflects our assessment of a continuing grim slump in the pharmaceutical group’s broader environment,” Fitch said. If you hold up a mirror to the group’s established position in an innovative pharmaceutical sector, a protected organic waiting room is treated unchecked in most cases. Fitch started the positive results with the strong performance of the best portfolio and the pipeline, which has a high probability.

Contact the author: [email protected]

DJG/jhe/brb

(END) Dow Jones Newswires

August 22, 2024 1:23 PM ET (5:23 PM GMT)